X-Chem, a US-based global company involved in innovative drug discovery services, announced on Tuesday the achievement of a milestone following Relay Therapeutics' initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical library (DEL) screen.
Relay Therapeutics, a US-based company involved in drug discovery, licensed an inhibitor of the oncology target phosphoinositide 3- kinase alpha (Pl3Ka) that was discovered through an X-Chem DEL screen. The inhibitor demonstrated differentiated pharmacology, mutant selectivity, a novel allosteric binding site and served as a starting point for Relay's innovative development of zovegalisib (RLY-2608), currently in a clinical trial. The companies say that the initiation of this Phase 3 trial represents a milestone under their Research Collaboration and License Agreement.
'The unique selectivity and binding site of RLY-2608 are a testament to the power of the X-Chem DEL platform to discover unique chemical matter with differentiated pharmacology,' said X-Chem CEO Karen Lackey. 'We are thrilled that our discovery platforms helped provide a starting point for a potential new treatment for patients with breast cancer. Hats off to the Relay team for having the drive and vision to push this project forward.'
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer